Thalia Therapeutics Plc (THAT.L)
Develops RNA-based medicines and delivery systems to treat cancer, heart disease, and inflammatory conditions.
0.65-0.04%Healthcare
StockGlow Score
Leaning Bullish
BearishBullish
1 year ago+44.4%
The outlook
Thalia Therapeutics is trading at 0.65p, sitting comfortably above both its 50- and 200-day moving averages, which signals positive short-term momentum. The stock sits roughly 42% of the way through its 52-week range, closer to its lows than highs. Analyst sentiment leans bullish overall, though coverage details are unavailable.
What’s behind the score
Price trendAbove its 50- & 200-day averages
52-week range42% of the way from its 52-week low to high
Market cap
$11.5M
52-wk high
1.00
52-wk low
0.40
50-day avg
0.64
200-day avg
0.56
Trailing P/E
—